PTGDS and mature T-cell and NK-cell non-Hodgkin lymphoma: Collectively, our observations firstly revealed the high expression and prognostic role of PTGDS in PTCL patients, and targeting PTGDS displayed excellent anti-lymphoma effects and enhanced the drug sensitivity of PTCL cells to Sorafenib in vitro and in vivo.